Aethlon Medical, Inc. (AEMD) Reaches $1.86 Yearly Low, Atlanta Capital Management Co Has Boosted Bright Horizons Fam Sol In D (BFAM) Holding By $336,210

May 29, 2017 - By Adrian Mccoy

The stock of Aethlon Medical, Inc. (NASDAQ:AEMD) hit a new 52-week low and has $1.80 target or 3.00% below today’s $1.86 share price. The 7 months bearish chart indicates high risk for the $15.03 million company. The 1-year low was reported on May, 29 by If the $1.80 price target is reached, the company will be worth $450,900 less. The stock increased 2.76% or $0.05 on May 26, reaching $1.86. About 37,334 shares traded or 8.18% up from the average. Aethlon Medical, Inc. (NASDAQ:AEMD) has declined 56.57% since May 29, 2016 and is downtrending. It has underperformed by 73.27% the S&P500.

Atlanta Capital Management Co Llc increased Bright Horizons Fam Sol In D (BFAM) stake by 1.25% reported in 2016Q4 SEC filing. Atlanta Capital Management Co Llc acquired 4,803 shares as Bright Horizons Fam Sol In D (BFAM)’s stock rose 9.89%. The Atlanta Capital Management Co Llc holds 387,950 shares with $27.16M value, up from 383,147 last quarter. Bright Horizons Fam Sol In D now has $4.60 billion valuation. The stock increased 0.33% or $0.25 on May 26, reaching $76.62. About 181,158 shares traded. Bright Horizons Family Solutions Inc (NYSE:BFAM) has risen 18.19% since May 29, 2016 and is uptrending. It has outperformed by 1.49% the S&P500.

Analysts await Aethlon Medical, Inc. (NASDAQ:AEMD) to report earnings on July, 5. They expect $-0.18 earnings per share, down 12.50% or $0.02 from last year’s $-0.16 per share. After $-0.15 actual earnings per share reported by Aethlon Medical, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Aethlon Medical, Inc. is a medical device firm focused on creating devices for cancer, infectious disease and other life-threatening conditions. The company has market cap of $15.03 million. The Firm operates through two divisions: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. It currently has negative earnings. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.

Among 6 analysts covering Bright Horizons (NYSE:BFAM), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Bright Horizons had 12 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was reinitiated by Credit Suisse on Wednesday, February 3 with “Outperform”. The firm earned “Neutral” rating on Friday, May 12 by Credit Suisse. JP Morgan upgraded the stock to “Overweight” rating in Monday, August 15 report. Barclays Capital maintained Bright Horizons Family Solutions Inc (NYSE:BFAM) rating on Wednesday, November 25. Barclays Capital has “Overweight” rating and $75 target. On Wednesday, November 2 the stock rating was downgraded by William Blair to “Market Weight”. The stock has “Outperform” rating by RBC Capital Markets on Monday, November 9. The stock of Bright Horizons Family Solutions Inc (NYSE:BFAM) has “Outperform” rating given on Tuesday, February 9 by RBC Capital Markets. The firm has “Market Perform” rating given on Friday, February 10 by William Blair. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, August 5.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.